Reliant AI’s Post

Great example of how AI will accelerate the scientific process! Congrats on the seed round Karl Moritz Hermann and Marc G. Bellemare!"You dump a thousand documents in, say you want this, that, and the other data out of them, and Reliant pores through them and finds that information — whether it’s perfectly labeled and structured or (far more likely) it isn’t. Then it pops all that data and any analyses you wanted done into a nice UI so you can dive down into individual cases."

Check out the latest blog from Miracle - on why we have to #defineai and #defineinnovation and support the industry with #dataintegrity and thoughtful #integration. 🔬 Unlock the secrets to biotech innovation! 🚀 Dive into the latest blog post exploring the transformative synergy of Data Integrations & AI. - Discover five key benefits reshaping the industry landscape. #Biotech #DataIntegrations #AI #Innovation

Endpoints News provided in-depth coverage on Sofinnova’s latest deal, leading a $35 million seed round for Bioptimus, a French startup working to create AI foundational models for biology. Edward Kliphuis, Partner in the Sofinnova Digital Medicine Strategy, cited the importance of data in this effort: “If you want to go to the foundational level of biology and train a model on that, if you think of how expensive it is to do RNA single cell or spatial omics, you already see that it’s not trivial to get sufficient data to train these models on,” he said in an interview. Kyle LaHucik, Senior Reporter at Endpoints, also interviewed Bioptimus General Manager and Co-Founder David Cahané, who explained the company's purpose, and its plans for the funds. Cahané is also chief solution officer at Owkin, which is providing data to Bioptimus. Bioptimus plans to release foundational models in protein, cell and histology modalities this year, Cahané said. The seed financing will largely go toward computing and data, with the company working to secure exclusive data deals with biomedical groups, he added. It’s working with Amazon Web Services (AWS) Services for the computing needed to train the models. “We believe that in a few years, maybe five, 10 years — a huge percentage of the data-driven research done in the biomedical ecosystem will be made on top of a foundation model, and we hope that Bioptimus’ foundation model will be the standard one in the ecosystem,” he said. Kliphuis said he got to know the Owkin team via a mutual interest in foundation models — and the fact that their offices are on the same street. Owkin, often touted as a French unicorn, has raised $300 million and struck deals with Sanofi, Bristol Myers Squibb, Merck and others. Also participating in the Bioptimus seed round were: Bpifrance, Headline, Hummingbird Ventures, NJF Capital, Owkin and Top Harvest Capital. French VCs Cathay Investments Limited, Frst and the tech entrepreneur @Xavier Niel also joined the round. Read full article: https://hubs.ly/Q02lQdJY0 Edward Kliphuis Simon Turner Javier Nunez-Vicandi Aishwarya Parthasarathy

🚀 Exciting News: Launch of SecondBrain! 🚀 After several months in “stealth mode,” we are thrilled to officially announce with Camille and Idriss, the launch of SecondBrain. 🎉 We met at LumApps 6 years ago where we had front row seats to witness a small french start-up become a global Gartner leader. Today, we’re putting all our efforts into solving a common problem in the  pharmaceutical industry: too much data, not enough resources and time to leverage it! 💡 At SecondBrain, we have developed an AI that analyzes the data available within pharmaceutical companies to help commercial and marketing teams identify and prioritize the most relevant actions at the right time to maximize business impact. 🎯 Follow our journey on SecondBrain or reach out to any of us if you work in the pharma industry 🙂 👉 Check out our story in the video below. 👉 Join us at the Microsoft AI Tour on October 22th, where we will be delivering a keynote on our new groundbreaking AI technology! #AI #innovation #SecondBrain #startup

From that "aha" moment to the top five things to do if #AI is disrupting your industry and even some chat about the best spinach pies in Greece, our CEO and co-founder Dimitrios Skaltsas shares this and more in a recent Authority Magazine interview with Cynthia Corsetti. Read it here ▶ https://lnkd.in/eZbJBBS3 #pharma #innovation #startup

🎉 EasySLR Secures Funding to Empower Researchers with AI-Driven Systematic Literature Reviews 🧠 We're excited to announce our successful pre-seed funding round from a group of angel investors, enabling us to expand our technology and support teams to better serve you. Read more: https://lnkd.in/gEFRVjg9 Discover how EasySLR can revolutionize your SLR process. Visit easyslr.com and get started with your free project today! #EasySLR #ISPORAnnual #SystematicReviews #AI #HealthcareResearch #Funding #Startup #SystematicLiteratureReview #SLR #LiteratureReview

I'm delighted to be joining RAVen (RA Ventures) as a Venture Partner focused on developing novel digital tools and machine learning system to empower the next generation of biotech companies. Over the past two years, I've written at lenght on: (i) The Need for an Operating System for Biopharma, encompassing better data processes, structures, tools, and more. (ii) The Unreasonable Effectiveness of Active Learning, and how ML in Biology is a powerful process efficiency for those who can harness it. (iii) The Power of Continually Fresh Data and State-of-the-Art Computation to drive better decisions in therapeutics development. While these themes have become more mainstream, too often we see them applied patchily, in name only, or solely in dedicated tech-focused biotechs. This necessarily undervalues their transformative power. If we believe in design/build/test, it must empower *every* biotech, not just platform plays or ones with tech-y investors. We must build technology that can accelerate the traditional biotech, focused on a single biological or technological insight. This is whence the drugs and the massive biomedical progress of the past two decades --- and this where (much of) the future is being built. Interested? Reach out. It's time to build. #biotech #ai #ml #biopharma #datascience

IMHO one of the best and most rewarding aspects of #marketing is the opportunity and responsibility of sharing people's stories. Learn more about how Intelligencia AI came to be and how to embrace #AI in the Q&A with our CEO and co-founder, Dimitrios Skaltsas. ⤵

🤔 A Venture Capital director/doctor (Namrata Rastogi, MD), a founder/doctor (Dr. Keith Tsui), a venture partner (Gemma Bloemen), and a serial entrepreneur (Janardan Prasad) walk into Google HQ to talk about AI in healthcare … What results in an incredibly balanced and insightful discussion on the current state of AI in healthcare and what the future might hold. Here were my key takeaways: 1️⃣ Data Privacy & Security: Emerging AI models can now be trained offline, reducing data leak risks. 2️⃣ The present: Lots of AI innovation is currently happening in administration, radiology, and primary care. 3️⃣ The future: As we move into the AI-enabled healthcare generation, these are some developments that were exciting to the panel: - Multimodal LLMs: Personalized health AI by integrating e-records, genetics, drug data, and more. - Preventative Health: Early risk detection by connecting data points before disease onset. - Evolving Data Privacy: Future preference for AI-only data access to minimize redundant questioning. - Explainability: AI-driven transparency in clinical decisions. 4️⃣ Challenges & Considerations: - The quality and accuracy of data input into LLMs are crucial—reducing "hallucinations" and improving output quality are key areas of focus. - Healthcare tech needs to be tailored not just for the industry but for specific local healthcare needs. Great to meet so many people Jesko Bartelt Isabel Van De Keere, PhD Filip Wolski Christina Bell

Check out my articles below - specifically the ones on AI, has been a lot of fun to research and write about! #Biotech #AI